You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海正藥業(600267.SH):與旺實生物簽訂戰略合作協議、委託生產框架協議 涉及VV116產品

格隆匯5月19日丨海正藥業(600267.SH)公佈,2022年5月19日,公司和上海旺實生物醫藥科技有限公司(“旺實生物”)簽訂了《戰略合作協議》及《委託生產框架協議》。

公吿顯示,上海君拓生物醫藥科技有限公司(“上海君拓”)和蘇州旺山旺水生物醫藥有限公司各持有旺實生物50%股權,上海君拓並表旺實生物。上海君拓為上海君實生物醫藥科技股份有限公司(“君實生物”)控股子公司,君實生物持有上海君拓68.125%股權。

此次簽訂的《戰略合作協議》屬於協議雙方基於合作意願而達成的戰略性、框架性約定,是對雙方權利義務原則性的約定,戰略合作方式不具有排他性。《委託生產框架協議》涉及的“代號JT001/VV116片和/或原料藥”(“VV116”)產品,公司不享有其所有權,僅為受託生產企業,具體數量、價格、特殊要求等將基於委託生產框架協議另行簽署商務合同,最終合同的簽署及簽署時間均存在不確定性,且相關生產線尚需辦理藥品委託生產註冊批准後,方可正式接受委託。VV116目前處於國際多中心的III期臨牀試驗研究階段,其用於治療新型冠狀病毒肺炎適應症尚未獲得國家藥監局批准,是否獲批存在不確定性。

上述協議涉及的戰略合作,有助於雙方在產品研發、生產、銷售等多個方面及相關領域拓展合作,提升公司業務發展空間,符合公司未來發展的需要,不存在損害公司及全體股東特別是中小股東利益的情形,協議的簽署對公司2022年度及未來財務狀況和經營成果的影響需視具體項目的推進和實施情況而定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account